Lipids & Metabolic

New cholesterol guidelines from the American Heart Association and the American College of Cardiology recommend adding ezetimibe and/or PCSK9 inhibitors to statin therapy for select high-risk patients, and also propose using coronary artery calcium (CAC) scoring as “a tiebreaker” to guide statin decisions for those at intermediate risk of atherosclerotic cardiovascular disease.

Up to a quarter of type 1 diabetes patients in England should have access to the Freestyle Libre, a flash glucose monitor that allows diabetics to check their blood sugar without the need for finger pricks. But a recent investigation by the BMJ has concluded that, in reality, just 3 to 5 percent of eligible patients have access to the potentially life-changing technology.

It’s not just what people eat—but when—that may influence their risk of developing prediabetes and high blood pressure, according to preliminary research scheduled to be presented Nov. 10 at the American Heart Association’s Scientific Sessions in Chicago.

A clinical and economic analysis of PCSK9 inhibitors in Canadian patients with atherosclerotic cardiovascular disease (ASCVD) is solidifying physician concerns that the lipid-lowering drugs might be too inaccessible—or too pricey—to benefit the average heart patient.

Roux-en-Y gastric bypass (RYGB) is linked to greater weight loss compared to two other bariatric procedures but also the highest risk of adverse events in the short term, researchers reported in the Annals of Internal Medicine.

Cannabis use is associated with double the risk of diabetic ketoacidosis among patients with type 1 diabetes, according to a research letter published Nov. 5 in JAMA Internal Medicine.

A 13-year study of type 2 diabetes patients has found metformin, one of the world’s highest-grossing anti-diabetic medications, could be protective against age-related macular degeneration, a leading cause of blindness in Americans older than 50.

Coronary artery calcium (CAC) scoring could be the key to determining which patients are most likely to benefit from statin therapy, according to a retrospective analysis published Nov. 5 in the Journal of the American College of Cardiology.

Biopharmaceutical company Amarin announced top-line results for its purified eicosapentaenoic acid (EPA) product in September, hailing the 25 percent risk reduction in a composite of cardiovascular outcomes associated with icosapent ethyl (Vascepa). But critics who commented on the results to Kaiser Health News worried the excitement over the trial is premature.

With the American Heart Association’s 2018 Scientific Sessions set for Nov. 10-12 in Chicago, two co-chairs of the programming committee previewed the themes of the meeting, its most anticipated clinical trials and the two new guidelines that will be unveiled.

Another drug with the potential to lower cholesterol beyond maximally tolerated statin therapy is preparing to enter the marketplace, STAT reported on Oct. 28.

A new study published in the European Journal of Preventive Cardiology identified a strong link between vitamin D levels in the blood and cardiorespiratory fitness (CRF)—with individuals in the top quartile of vitamin D being almost three times more fit than those in the bottom quartile after adjustment for clinical characteristics.